Lipid-Based Solutions to Increase Bioavailability Presented at Drug Delivery and Formulation Summit

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Dr. Vincent Plassat, Scientific Affairs Manager, will present a workshop at the upcoming Drug Delivery and Formulation Summit, to be held at the Swissôtel, Düsseldorf, Germany on the 9th – 11th February, 2015.

Somerset, N.J. (PRWEB) February 05, 2015

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Dr. Vincent Plassat, Scientific Affairs Manager, will present a workshop at the upcoming Drug Delivery and Formulation Summit, to be held at the Swissôtel, Düsseldorf, Germany, on the 9th – 11th February, 2015.

Dr. Plassat's session, on February 10th at 10.25 a.m., is entitled "Accelerating the development of compounds with bioavailability limitations" and will discuss the development of orally-delivered, lipid-based systems that can be used to improve the bioavailability of New Chemical Entities that offer therapeutic promise for patients, but exhibit limiting physico-chemical attributes for conventional, solid oral dose delivery.

Dr. Plassat joined Catalent in 2013, initially as a formulation scientist, drawing upon his experience in lipid-based softgel development for the oral delivery of macromolecules, before becoming Scientific Affairs Manager. Prior to joining Catalent, he worked at OTR3, a Paris-based startup company, developing targeted therapies.

Dr. Plassat is a pharmacist, and received a Ph.D. from the University of Paris Sud in Pharmaceutical Technologies.

For more information on the Drug Delivery and Formulation Summit, visit: http://www.ddfevent.com and to arrange a meeting with Dr. Plassat, contact Richard Kerns at NEPR- [email protected]

About Catalent

Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

 

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.